ImmuCell Corporation (NASDAQ:ICCC) Sees Significant Decline in Short Interest

ImmuCell Corporation (NASDAQ:ICCC) was the target of a significant decrease in short interest in December. As of December 31st, there was short interest totaling 7,780 shares, a decrease of 49.5% from the December 15th total of 15,418 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 44,325 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 44,325 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Steadtrust LLC purchased a new stake in ImmuCell Corporation (NASDAQ:ICCC) during the third quarter, according to its most recent filing with the SEC. The fund purchased 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned about 0.35% of ImmuCell as of its most recent filing with the SEC. Institutional investors own 13.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of ImmuCell in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

ImmuCell Price Performance

Shares of NASDAQ ICCC traded down $0.28 during mid-day trading on Friday, reaching $6.36. The company’s stock had a trading volume of 40,911 shares, compared to its average volume of 38,308. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.21 and a quick ratio of 1.76. ImmuCell has a 52 week low of $4.28 and a 52 week high of $7.60. The stock has a fifty day moving average of $5.75 and a two-hundred day moving average of $6.12. The firm has a market capitalization of $57.53 million, a PE ratio of 24.46 and a beta of 0.18.

ImmuCell (NASDAQ:ICCC) last issued its earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%. The business had revenue of $5.51 million for the quarter.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.